Spots Global Cancer Trial Database for epirubicine, oxaliplatin, capecitabine, panitumumab
Every month we try and update this database with for epirubicine, oxaliplatin, capecitabine, panitumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma | NCT01351038 | KRAS Wild Type Resectable Type... | Epirubicine, Ox... | 18 Years - 65 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma | NCT01351038 | KRAS Wild Type Resectable Type... | Epirubicine, Ox... | 18 Years - 65 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma | NCT01351038 | KRAS Wild Type Resectable Type... | Epirubicine, Ox... | 18 Years - 65 Years | Arbeitsgemeinschaft medikamentoese Tumortherapie |